相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer
Yuxiang Li et al.
CELLULAR IMMUNOLOGY (2020)
Inhibition of Cholesterol Esterification Enzyme Enhances the Potency of Human Chimeric Antigen Receptor T Cells against Pancreatic Carcinoma
Lei Zhao et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
Raffit Hassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells
Elham Masoumi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Killing cervical cancer cells by specific chimeric antigen receptor-modified T cells
Yue He et al.
JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2020)
Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model
Astero Klampatsa et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma
Masoud Sotoudeh et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Mohamed-Reda Benmebarek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer
Jiang Lv et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Chimeric Antigen Receptor T Cell Therapy for Solid Tumors: Current Status, Obstacles and Future Strategies
Benjamin Heyman et al.
CANCERS (2019)
Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer
James Clarke et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers
Andrew R. Haas et al.
MOLECULAR THERAPY (2019)
Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor
Zhiwei Zhang et al.
CELL DEATH & DISEASE (2019)
MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
Livingstone Fultang et al.
EBIOMEDICINE (2019)
Teaching an old dog new tricks: next-generation CAR T cells
Nicholas Tokarew et al.
BRITISH JOURNAL OF CANCER (2019)
CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
Wanghong Hu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells
Ruocong Zhao et al.
ONCOIMMUNOLOGY (2019)
An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
Steven Feins et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Mesothelin as a biomarker for targeted therapy
Jiang Lv et al.
BIOMARKER RESEARCH (2019)
Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells
Y. Lai et al.
LEUKEMIA (2018)
Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation
Yu-Li Chen et al.
CANCER LETTERS (2018)
Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer
Jiangchuan He et al.
CELLULAR IMMUNOLOGY (2018)
CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Miliotou N. Androulla et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2018)
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
Gregory L. Beatty et al.
GASTROENTEROLOGY (2018)
Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy
Chien-Fu Hung et al.
HUMAN GENE THERAPY (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects
Yuki Kagoya et al.
NATURE MEDICINE (2018)
Inhibition of Interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro
Ramesh B. Batchu et al.
SURGERY (2018)
Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy
Erhao Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
Tyvette S. Hilliard
CANCERS (2018)
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses
Keisuke Watanabe et al.
JCI INSIGHT (2018)
Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
Le Qin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
Hao Chen et al.
MOLECULES (2017)
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem et al.
NATURE (2017)
Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma
Jie-Ying Xu et al.
TUMOR BIOLOGY (2017)
Amatuximab and novel agents targeting mesothelin for solid tumors
Paolo Baldo et al.
ONCOTARGETS AND THERAPY (2017)
Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
Hua Jiang et al.
PROTEIN & CELL (2017)
Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Si Li et al.
CLINICAL CANCER RESEARCH (2017)
Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator
M-C Chang et al.
GENE THERAPY (2016)
Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection
Anubha Gupta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
Xiaojun Liu et al.
CANCER RESEARCH (2016)
A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial
Marissa Mayor et al.
IMMUNOTHERAPY (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Colin D. Weekes et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
Kheng Newick et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
piggyBac-ing models and new therapeutic strategries
Lauren E. Woodard et al.
TRENDS IN BIOTECHNOLOGY (2015)
High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
Anish Thomas et al.
ONCOTARGET (2015)
Functional Genomic mRNA Profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types
Laetitia E. Lamberts et al.
ONCOTARGET (2015)
Mesothelin expression is associated with poor outcomes in breast cancer
Yun R. Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma
Stefan S. Kachala et al.
CLINICAL CANCER RESEARCH (2014)
Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2014)
Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2014)
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
Sven Golfier et al.
MOLECULAR CANCER THERAPEUTICS (2014)
An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
Suzie J. Scales et al.
MOLECULAR CANCER THERAPEUTICS (2014)
In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer
Kevin Hollevoet et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Immunotherapy-induced CD8(+) T Cells Instigate Immune Suppression in the Tumor
A. J. Robert McGray et al.
MOLECULAR THERAPY (2014)
ERC/mesothelin is expressed in human gastric cancer tissues and cell lines
Tomoaki Ito et al.
ONCOLOGY REPORTS (2014)
Expansion of Anti-Mesothelin Specific CD4+ and CD8+ T Cell Responses in Patients with Pancreatic Carcinoma
Yuan Chen et al.
PLOS ONE (2014)
Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival
Gary Tozbikian et al.
PLOS ONE (2014)
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
Prasad S. Adusumilli et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The Role of Mesothelin in Tumor Progression and Targeted Therapy
Zhewei Tang et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2013)
Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases
Matthew J. Riese et al.
CANCER RESEARCH (2013)
Mesothelin Expression Is a Prognostic Factor in Cholangiocellular Carcinoma
Ryohei Nomura et al.
INTERNATIONAL SURGERY (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
Evripidis Lanitis et al.
CANCER IMMUNOLOGY RESEARCH (2013)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Marcela V. Maus et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
Hollie J. Pegram et al.
BLOOD (2012)
Mesothelin, a novel immunotherapy target for triple negative breast cancer
Julia Tchou et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer
T. Einama et al.
BRITISH JOURNAL OF CANCER (2012)
Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma
Atsushi Shimizu et al.
CANCER SCIENCE (2012)
A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
Dung T. Le et al.
CLINICAL CANCER RESEARCH (2012)
Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer
Futoshi Kawamata et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Mesothelin expression correlates with prolonged patient survival in gastric cancer
Kenji Baba et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor
Evripidis Lanitis et al.
MOLECULAR THERAPY (2012)
A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers
Jordan M. Winter et al.
PLOS ONE (2012)
Mesothelin as a Potential Therapeutic Target in Human Cholangiocarcinoma
Liping Yu et al.
Journal of Cancer (2012)
Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation
Uddalak Bharadwaj et al.
CARCINOGENESIS (2011)
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2011)
The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor
Z. Jin et al.
GENE THERAPY (2011)
Costimulation by chimeric antigen receptors revisited: the T cell antitumor response benefits from combined CD28-OX40 signalling
Andreas A. Hombach et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression
Uddalak Bharadwaj et al.
MOLECULAR CANCER (2011)
IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice
John C. Markley et al.
BLOOD (2010)
Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor
Yangbing Zhao et al.
CANCER RESEARCH (2010)
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2010)
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy
Raffit Hassan et al.
LUNG CANCER (2010)
Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway
Ming-Cheng Chang et al.
BIOCHEMICAL JOURNAL (2009)
High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma
W-F Cheng et al.
BRITISH JOURNAL OF CANCER (2009)
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2009)
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
Carmine Carpenito et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Mesothelin targeted cancer immunotherapy
Raffit Hassan et al.
EUROPEAN JOURNAL OF CANCER (2008)
Mesothelin-Induced Pancreatic Cancer Cell Proliferation Involves Alteration of Cyclin E via Activation of Signal Transducer and Activator of Transcription Protein 3
Uddalak Bharadwaj et al.
MOLECULAR CANCER RESEARCH (2008)
Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells
Norihisa Uehara et al.
MOLECULAR CANCER RESEARCH (2008)
Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer
Min Li et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy
Hector Alvarez et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2008)
Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells
Daniel Steinbach et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma
Louis A. Dainty et al.
GYNECOLOGIC ONCOLOGY (2007)
Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma
Kei Kushitani et al.
PATHOLOGY INTERNATIONAL (2007)
Mesothelin expression in human lung cancer
Mitchell Ho et al.
CLINICAL CANCER RESEARCH (2007)
S-100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct
Huicong Zhao et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2007)
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
Jennifer A. A. Gubbels et al.
MOLECULAR CANCER (2006)
The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies
ML Galloway et al.
HISTOPATHOLOGY (2006)
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma
MJ Yen et al.
CLINICAL CANCER RESEARCH (2006)
Localization of mesothelin in epithelial ovarian cancer
R Hassan et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2005)
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
A Rump et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays
SL Swierczynski et al.
HUMAN PATHOLOGY (2004)
Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas
HF Frierson et al.
HUMAN PATHOLOGY (2003)
Value of mesothelin immunostaining in the diagnosis of mesothelioma
NG Ordóñez
MODERN PATHOLOGY (2003)
Application of mesothelin immunostaining in tumor diagnosis
NG Ordonez
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
Mesothelin is not required for normal mouse development or reproduction
TK Bera et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
